Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in BFLY.
← Back to Free Index

BFLY

Analysis as of: 2026-03-28
Butterfly Network, Inc.
Butterfly sells handheld whole-body ultrasound probes, cloud workflow software, and partner development tools for clinicians, health systems, and adjacent device makers.
ai enterprise healthcare medical devices software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Imaging platform optionality with real adoption gates
The upside case is a shift from selling probes to monetizing the operating layer around bedside imaging. That can work, but only if software, partner licensing, and new care settings become repeatable before larger incumbents compress pricing.

Analysis

Thesis
Butterfly can grow from a handheld ultrasound vendor into a regulated imaging workflow and partner-licensing business; if probe placements, software attach, and adjacent channels compound together, revenue can reach a much larger scale and support a meaningful rerating over five years.
Last Economy Alignment
Cheaper AI should expand ultrasound use by lowering training and workflow friction, and Butterfly owns a real hardware control point plus regulated software. The cap on the score is that large incumbents can still bundle hardware and compress pricing unless Butterfly proves durable workflow and licensing capture.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
2.9x (from 5 most recent analyses)
Reasoning
The upside does not require Butterfly to dominate ultrasound. It requires three things to work together: steady core probe expansion, deeper software attachment inside health systems, and at least one adjacent channel such as partner licensing or home-based care becoming repeatable. If that mix shifts away from mostly device revenue, investors can value it more like a recurring imaging platform than a single-product medtech vendor.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risk is not whether Butterfly’s core probe works; it does. The real risk is commercial conversion: can the company turn enterprise workflow, partner licensing, government access, and home-based care into repeatable revenue before incumbents use bundling, sales reach, and procurement leverage to cap pricing power. Integration friction and trust/compliance gates are the key throttles.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.42
They own a real piece of hardware that AI cannot replace, and they are trying to wrap it with workflow, security, and developer tools that get more valuable as ultrasound spreads. The risk is that bigger imaging vendors can bundle similar products and hospitals may not pay up unless Butterfly becomes part of the compliance and operating workflow.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$5.56
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case